Aliases & Classifications for Morbid Obesity

MalaCards integrated aliases for Morbid Obesity:

Name: Morbid Obesity 38 12 29 6 15
Obesity, Morbid 44 73
Severe Obesity 12 15
Obesity Morbid 55

Classifications:



External Ids:

Disease Ontology 12 DOID:11981
ICD9CM 35 278.01
MeSH 44 D009767
NCIt 50 C34858
UMLS 73 C0028756

Summaries for Morbid Obesity

MalaCards based summary : Morbid Obesity, also known as obesity, morbid, is related to liver disease and fatty liver disease, and has symptoms including obesity, metabolically benign An important gene associated with Morbid Obesity is PPARG (Peroxisome Proliferator Activated Receptor Gamma), and among its related pathways/superpathways are Signaling by GPCR and Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.. The drugs Dexmedetomidine and Methylcobalamin have been mentioned in the context of this disorder. Affiliated tissues include liver, bone and testes, and related phenotypes are adipose tissue and behavior/neurological

Related Diseases for Morbid Obesity

Diseases related to Morbid Obesity via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 263)
# Related Disease Score Top Affiliating Genes
1 liver disease 30.4 ADIPOQ INS LEP LEPR
2 fatty liver disease 30.3 ADIPOQ INS LEP LEPR
3 gastroesophageal reflux 30.3 CCK GCG GHRL PYY
4 nonalcoholic steatohepatitis 30.2 ADIPOQ INS LEP
5 nonalcoholic fatty liver disease 30.0 ADIPOQ CRP INS LEP PPARG RETN
6 obesity-hypoventilation syndrome 29.9 ADIPOQ LEP RETN
7 arteries, anomalies of 29.8 ADIPOQ CRP INS LEP PPARG
8 acanthosis nigricans 29.7 ADIPOQ INS LEP PPARG
9 fatty liver disease, nonalcoholic 1 29.7 ADIPOQ INS LEP RETN
10 chronic kidney failure 29.7 ADIPOQ CRP INS LEP
11 dumping syndrome 29.6 GCG INS PYY
12 nutritional deficiency disease 29.6 CRP GHRL LEP
13 hyperuricemia 29.6 ADRB3 CRP INS
14 abdominal obesity-metabolic syndrome 1 29.6 ADIPOQ INS LEP PPARG
15 severe pre-eclampsia 29.6 ADIPOQ LEP LEPR
16 sleep apnea 29.6 ADIPOQ CRP GHRL HCRT INS LEP
17 hyperinsulinism 29.5 GHRL INS LEP
18 acute pancreatitis 29.5 CCK CRP LPL
19 pancreatitis 29.5 CCK CRP LPL
20 gestational diabetes 29.5 ADIPOQ ADRB3 INS LEP RETN
21 eating disorder 29.5 ADIPOQ CCK GHRL LEP LEPR MC4R
22 apnea, obstructive sleep 29.4 ADIPOQ CRP HCRT INS LEP
23 myocardial infarction 29.4 ADIPOQ CRP GHRL INS RETN
24 diabetes mellitus 29.4 ADIPOQ ADRB3 CRP GCG GHRL INS
25 hyperglycemia 29.4 ADIPOQ GCG INS LEP PPARG
26 celiac disease 1 29.2 CCK FABP2 GHRL PYY
27 anorexia nervosa 29.0 ADIPOQ CCK GHRL HCRT LEP LEPR
28 prader-willi syndrome 28.9 ADIPOQ CCK GCG GHRL HCRT INS
29 diabetes mellitus, noninsulin-dependent 28.1 ADIPOQ ADRB3 CRP FABP2 GCG GHRL
30 body mass index quantitative trait locus 11 27.3 ADIPOQ ADRB3 CCK CRP FABP2 FTO
31 morbid obesity and spermatogenic failure 12.6
32 leptin deficiency or dysfunction 11.7
33 leptin receptor deficiency 11.4
34 obesity, early-onset, with adrenal insufficiency and red hair 10.9
35 obesity due to congenital leptin deficiency 10.8
36 congenital leptin deficiency 10.8
37 degos 'en cocarde' erythrokeratoderma 10.7
38 malignant otitis externa 10.3 CRP INS
39 lipodystrophy, familial partial, type 1 10.2 INS LEP PPARG
40 complete generalized lipodystrophy 10.2 INS LEP PPARG
41 type 1 diabetes mellitus 15 10.2 GCG INS
42 body mass index quantitative trait locus 10 10.2
43 body mass index quantitative trait locus 14 10.2
44 body mass index quantitative trait locus 18 10.2
45 body mass index quantitative trait locus 19 10.2
46 lipodystrophy, congenital generalized, type 1 10.2 ADIPOQ INS LEP
47 abdominal obesity-metabolic syndrome quantitative trait locus 2 10.2 CRP INS LEP
48 familial partial lipodystrophy 10.2 INS LEP PPARG
49 idiopathic edema 10.2 ADIPOQ INS PPARG
50 hyperinsulinemic hypoglycemia, familial, 7 10.2 GCG INS

Graphical network of the top 20 diseases related to Morbid Obesity:



Diseases related to Morbid Obesity

Symptoms & Phenotypes for Morbid Obesity

UMLS symptoms related to Morbid Obesity:


obesity, metabolically benign

MGI Mouse Phenotypes related to Morbid Obesity:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 adipose tissue MP:0005375 10.37 ADIPOQ ADRB3 CEP19 FABP2 FTO GHRL
2 behavior/neurological MP:0005386 10.32 ADIPOQ ADRB3 CCK CEP19 FTO GHRL
3 homeostasis/metabolism MP:0005376 10.32 ADIPOQ ADRB3 CCK CEP19 CRP FABP2
4 growth/size/body region MP:0005378 10.25 ADIPOQ ADRB3 CEP19 FABP2 FTO HCRT
5 cardiovascular system MP:0005385 10.11 ADIPOQ CRP HCRT INS LEP LEPR
6 endocrine/exocrine gland MP:0005379 10.09 ADIPOQ ADRB3 CCK FTO GHRL INS
7 immune system MP:0005387 10.02 ADIPOQ CRP FTO INS LEP LEPR
8 liver/biliary system MP:0005370 9.96 ADIPOQ FABP2 FTO INS LEP LEPR
9 muscle MP:0005369 9.7 ADIPOQ HCRT INS LEP LEPR LPL
10 renal/urinary system MP:0005367 9.56 ADIPOQ CCK FABP2 FTO INS LEP
11 skeleton MP:0005390 9.28 ADIPOQ FTO INS LEP LEPR MC3R

Drugs & Therapeutics for Morbid Obesity

Drugs for Morbid Obesity (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 357)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
2
Methylcobalamin Approved, Experimental, Investigational Phase 4,Phase 2,Phase 3 13422-55-4
3
Hydroxocobalamin Approved Phase 4,Phase 2,Phase 3 13422-51-0 11953898 44475014
4
Morphine Approved, Investigational Phase 4,Phase 2,Phase 3 57-27-2 5288826
5
Acetaminophen Approved Phase 4,Phase 3,Phase 1,Not Applicable,Early Phase 1 103-90-2 1983
6
Midazolam Approved, Illicit Phase 4,Not Applicable 59467-70-8 4192
7
Dalteparin Approved Phase 4 9005-49-6
8
Enoxaparin Approved Phase 4,Phase 1,Phase 2 9005-49-6 772
9
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
10
chenodeoxycholic acid Approved Phase 4,Phase 2,Phase 1 474-25-9 10133
11
Heparin Approved, Investigational Phase 4,Not Applicable 9005-49-6 772 46507594
12
Nadroparin Approved, Investigational Phase 4
13
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 94-09-7, 1994-09-7 2337
14
Rocuronium Approved Phase 4,Phase 2,Not Applicable 119302-91-9, 143558-00-3 441290
15 tannic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable
16
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 2078-54-8 4943
17
Liraglutide Approved Phase 4,Not Applicable 204656-20-2 44147092
18
Ursodeoxycholic acid Approved, Investigational Phase 4,Not Applicable 128-13-2 31401
19
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 437-38-7 3345
20
Ketamine Approved, Vet_approved Phase 4,Phase 3 6740-88-1 3821
21
Neostigmine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 59-99-4 4456
22
Methylene blue Approved, Investigational Phase 4,Phase 1,Phase 2 61-73-4
23
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
24
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
25
Micafungin Approved, Investigational Phase 4 235114-32-6 3081921 477468
26
Amphotericin B Approved, Investigational Phase 4 1397-89-3 5280965 14956
27
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2 73590-58-6 4594
28
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7 4594 9579578
29
Iron Approved Phase 4,Phase 2,Phase 3,Not Applicable 7439-89-6 23925
30
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 3,Not Applicable 76-42-6 5284603
31
Ibuprofen Approved Phase 4 15687-27-1 3672
32
Verapamil Approved Phase 4 52-53-9 2520
33
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
34
Pasireotide Approved Phase 4 396091-73-9 9941444
35
Ropivacaine Approved Phase 4,Not Applicable 84057-95-4 175805 71273
36
Etidronic acid Approved Phase 4 7414-83-7, 2809-21-4 3305
37
Octreotide Approved, Investigational Phase 4 83150-76-9 383414 6400441
38
Methyltestosterone Approved Phase 4 58-18-4 6010
39
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
40
Testosterone Approved, Investigational Phase 4 58-22-0 6013
41
Testosterone enanthate Approved Phase 4 315-37-7 9416
42
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3 59-30-3 6037
43
Cyanocobalamin Approved, Nutraceutical Phase 4,Phase 2,Phase 3 68-19-9 44176380
44
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 11103-57-4, 68-26-8 445354
45
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
46
Cobalamin Experimental Phase 4,Phase 2,Phase 3 13408-78-1 6438156
47 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
48 Adrenergic Agonists Phase 4
49 Adrenergic alpha-2 Receptor Agonists Phase 4
50 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 594)
# Name Status NCT ID Phase Drugs
1 Impact of the Preservation of the Gastric Antrum in the Technique of Sleeve Gastrectomy for the Treatment of the Morbid Obesity Unknown status NCT01550601 Phase 4
2 Pharmacokinetics of Dexmedetomidine in Morbid Obesity Unknown status NCT01864187 Phase 4 Dexmedetomidine
3 Vitamin Deficiencies and Suppletion in Morbid Obesity Unknown status NCT02270749 Phase 4 Hydroxocobalamin;FitForMe vitamin B12
4 Evaluation of the Effects of Laying Early a Gastric Band on the Prevention of Morbid Obesity Randomized Checked Against Standard Management of Obesity in This Population. Unknown status NCT01700738 Phase 4
5 VAS Correlation With BMI Unknown status NCT02017314 Phase 4 Morphine
6 Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Sleeve Gastrectomy Unknown status NCT00667706 Phase 4
7 Pharmacokinetics of Acetaminophen in Morbidly Obese Patients Unknown status NCT01764555 Phase 4 acetaminophen 2 g
8 CYP3A4 Metabolism Before and After Surgery Induced Weight Loss Using Midazolam as Model Drug Unknown status NCT01519726 Phase 4 Midazolam
9 Anti Xa Levels Under Two Different Regimens of Enoxaparin VTE Prophylaxis After Sleeve Gastrectomy for Morbid Obesity Unknown status NCT01970202 Phase 4 40mg Enoxaparin;60mg Enoxaparin
10 Aromatase Inhibitors and Weight Loss in Severely Obese Hypogonadal Male Veterans (Pilot) Unknown status NCT02959853 Phase 4 Anastrazole
11 Banded Versus Conventional Laparoscopic Roux-en-Y (GABY) Unknown status NCT01015469 Phase 4
12 Effect of Bile Acids and Bile Acid Sequstrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass Unknown status NCT02952963 Phase 4 Chenodeoxycholic Acid;Colesevelam
13 Prophylaxis of Venous Thromboembolism After Bariatric Surgery Unknown status NCT02295150 Phase 4 Nadroparin
14 Effect of Laparoscopic Sleeve Gastrectomy in the Morbidly Obese, Kidney Transplant Candidate Unknown status NCT01913392 Phase 4
15 Laparoscopic Bariatric Surgery: Impact of Deep Neuromuscular Block on Surgical Conditions Unknown status NCT02118844 Phase 4 rocuronium
16 Obesity Cohort : Medical Follow-up of Severe or Morbid Obese Patients Undergoing Bariatric Surgery Unknown status NCT02310178 Phase 4
17 Clinical Trial Between Laparoscopic Gastric Bypass and Laparoscopic Vertical Banded Gastroplasty for Morbid Obesity Completed NCT01639677 Phase 4
18 Post Implantation/Post Market Evaluation of the Swedish Adjustable Gastric Band Completed NCT00543140 Phase 4
19 Surgical Conditions During Laparoscopic Bariatric Surgery Completed NCT02703909 Phase 4 Rocuronium
20 Omega-3 Fatty Acids in Bariatric Gastric Bypass Surgery: Effect on Liver Volume, Immune Response and Erythrocyte Function Completed NCT02206256 Phase 4 Omega-3 fatty acid capsules
21 Investigations on the Influence of Bariatric Surgery on the Metabolism and Absorption of Atorvastatin Completed NCT00331565 Phase 4
22 Dosing Obese With Noxafil® Under a Trial (DONUT) Completed NCT03246386 Phase 4 Posaconazole Injection [Noxafil] 300mg;Posaconazole Injection [Noxafil] 400mg
23 Micafungin Pharmacokinetics in Obese Patients Completed NCT03102658 Phase 4 Micafungin
24 Liposomal Amphotericin B (AmBisome) Pharmacokinetics Given as a Single Intravenous Dose to Obese Patients (ASPEN) Completed NCT02320604 Phase 4 Administration of study drug
25 Garcinia Mangostana Extracts in the Management of Weight Loss Completed NCT02823561 Phase 4
26 Population PK/PD of Propofol in the Morbidly Obese Patient Completed NCT00395681 Phase 4 Diprivan
27 Preoperative Condition in Giant Obese Patients Completed NCT02616003 Phase 4 Liraglutide
28 Study to Compare the Bioavailability (Amount of Drug Reaching the Blood) of Omeprazole 20 mg Before and After Undergoing Surgery for Morbid Obesity Completed NCT03378960 Phase 4 Omeprazole 20mg
29 Effects of Bile Acids on GLP-1 Secretion After Roux-en-Y Gastric Bypass Completed NCT02340247 Phase 4 Ursodeoxycholic Acid;Chenodeoxycholic Acid
30 Use Of Esomeprazole In Postoperative Bariatric Surgery Patients Users And Non-Users Of Nonsteroidal Anti-Inflammatory Drugs (NSAIDS) Completed NCT00608712 Phase 4 Esomeprazole
31 Ketamine for Pain Relief in Bariatric Surgery Completed NCT03052673 Phase 4 Fentanyl;ketamine
32 The Use of Liposomated Iron After Bariatric Surgery in Patients That Are Receiving Parentheral Therapy With Iron Completed NCT02390921 Phase 4 Fisiogen Ferro Forte;Venofer
33 A Trial of the Cost Effectiveness of IV Acetaminophen in Bariatric Surgery Completed NCT02233400 Phase 4 Acetaminophen
34 Comparisons of iv Ibuprofen and iv Paracetamol During Bariatric Surgery Completed NCT02778958 Phase 4 paracetamol;ibuprofen
35 Treatment of Hypoglycemia Following Gastric Bypass Surgery Completed NCT02527993 Phase 4 Glucobay (acarbose);Januvia (sitagliptin);Verapamil HEXAL (verapamil);Victoza (liraglutide);Signifor (pasireotide)
36 Study to Evaluate Weight-based Enoxaparin Dosing in Obese Medical Patients at Risk for DVT Completed NCT00585182 Phase 4 Enoxaparin 0.5 mg/kg once daily
37 Weight Loss With Risedronate for Bone Health Recruiting NCT03411902 Phase 4 Risedronate Sodium 150 MG
38 DPE Technique in Labor Epidural for Morbidly Obese Women Recruiting NCT03074695 Phase 4 Dural puncture epidural (DPE);Standard Epidural (EPL)
39 Effects of Bile Acids and Bile Acid Sequestrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass Recruiting NCT02876484 Phase 4 Colesevelam;Chenodeoxycholic Acid
40 Impact of Sugammadex vs. Neostigmine Reversal on Post-Operative Recovery and Complications Recruiting NCT03679611 Phase 4 Sugammadex Sodium;Neostigmine
41 Gut Hormones as Mediators of Different Weight Loss Responses After Roux-en-Y Gastric Bypass Active, not recruiting NCT02374632 Phase 4
42 Testosterone in Bariatric Patients Not yet recruiting NCT03721497 Phase 4 Testosterone Undecanoate
43 Study of Proton Pump Inhibitors (PPI) to Prevent Strictures After Gastric Bypass Surgery Withdrawn NCT00361985 Phase 4 Esomeprazole;Esomeprazole
44 Laparoscopic Sleeve Gastrectomy Plus Weight Watchers vs. Weight Watchers Alone in Underserved Minority Women Withdrawn NCT01929850 Phase 4
45 Bariatric Arterial Embolization for Morbid Obesity Unknown status NCT02786108 Phase 3
46 Stapled vs Hand Sewn Anastomosis in Roux en Y Gastric Bypass for Morbid Obesity: Randomized Clinical Trial Unknown status NCT02077517 Phase 3
47 Laparoscopic Adjustable Gastric Banding in Adolescents Unknown status NCT01619488 Phase 3
48 Sevoflurane Versus Intravenous Anaesthetic Agents in Morbid Obese Patients Unknown status NCT01279499 Phase 2, Phase 3 Sevoflurane;Sevoflurane;Propofol- Remifentanyl;Propofol, Remifentanyl
49 Efficiency of TISSEEL for Sleeve Gastrectomy Complications Unknown status NCT01613664 Phase 3 tisseel
50 Transoral Gastroplasty for the Treatment of Morbid Obesity Unknown status NCT00661245 Phase 3

Search NIH Clinical Center for Morbid Obesity

Cochrane evidence based reviews: obesity, morbid

Genetic Tests for Morbid Obesity

Genetic tests related to Morbid Obesity:

# Genetic test Affiliating Genes
1 Morbid Obesity 29

Anatomical Context for Morbid Obesity

MalaCards organs/tissues related to Morbid Obesity:

41
Liver, Bone, Testes, Brain, Heart, Thyroid, Kidney

Publications for Morbid Obesity

Articles related to Morbid Obesity:

(show top 50) (show all 1235)
# Title Authors Year
1
Reliability of International Classification of Diseases, Ninth Edition, Codes to Detect Morbid Obesity in Patients Undergoing Total Hip Arthroplasty. ( 29885969 )
2018
2
Binge eating disorder and morbid obesity are associated with lowered mu-opioid receptor availability in the brain. ( 29655552 )
2018
3
Is perceived intolerance to milk and wheat associated with the corresponding IgG and IgA food antibodies? A cross sectional study in subjects with morbid obesity and gastrointestinal symptoms. ( 29378512 )
2018
4
Decrease of Plasma Soluble (Pro)renin Receptor by Bariatric Surgery in Patients with Obstructive Sleep Apnea and Morbid Obesity. ( 29649379 )
2018
5
Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss in Patients With Morbid Obesity: The SM-BOSS Randomized Clinical Trial. ( 29340679 )
2018
6
The trends and prevalence of obesity and morbid obesity among Australian school-aged children, 1985-2014. ( 29667237 )
2018
7
Effect of Manual Caudal and Downward Displacement of Lower Cervical Adipose Tissue on Laryngoscopic Grade of Patients with Morbid Obesity. ( 29868457 )
2018
8
The impact of living with morbid obesity on psychological need frustration: A study with bariatric patients. ( 29790653 )
2018
9
Abdominal Pain After Roux-En-Y Gastric Bypass for Morbid Obesity. ( 29739280 )
2018
10
Single Incision Versus Conventional Laparoscopic Sleeve Gastrectomy for Morbid Obesity: A Meta-Analysis. ( 29389227 )
2018
11
Cost-effectiveness analysis of bariatric surgery for morbid obesity in Belgium. ( 29271279 )
2018
12
A Tuscan general with morbid obesity. ( 29404906 )
2018
13
Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity. ( 29335933 )
2018
14
Weight Loss Surgery Reduces Healthcare Resource Utilization and All-Cause Inpatient Mortality in Morbid Obesity: a Propensity-Matched Analysis. ( 29931480 )
2018
15
Lifestyle intervention for morbid obesity: effects on liver steatosis, inflammation and fibrosis. ( 29878845 )
2018
16
Systematic assessment of decision analytic models for the cost-effectiveness of bariatric surgery for morbid obesity. ( 29735347 )
2018
17
Morbid obesity and functional status as predictors of surgical complication after renal transplantation. ( 28622834 )
2018
18
A perioperative care map improves outcomes in patients with morbid obesity undergoing major surgery. ( 29195738 )
2018
19
Effects of multidisciplinary interventions on weight loss and health outcomes in children and adolescents with morbid obesity. ( 29701298 )
2018
20
Morbid obesity: potential effects of hormonal contraception. ( 29777662 )
2018
21
Lower Extremity Geometry in Morbid Obesity-Considerations for Total Knee Arthroplasty. ( 29705683 )
2018
22
Comment on: systematic assessment of decision analytic models for the cost-effectiveness of bariatric surgery for morbid obesity. ( 29703504 )
2018
23
Associations of Prepregnancy Morbid Obesity and Prenatal Depression with Gestational Weight Gain. ( 29298365 )
2018
24
Remission of Sjogren's Syndrome after Roux-en-Y Gastric Bypass for Morbid Obesity. ( 29248981 )
2018
25
Brown adipose tissue lipid metabolism in morbid obesity: Effect of bariatric surgery-induced weight loss. ( 29377423 )
2018
26
Morbid obesity and type 2 diabetes alter intestinal fatty acid uptake and blood flow. ( 29352513 )
2018
27
Stomach Intestinal Pylorus-Sparing Surgery for Morbid Obesity. ( 29398898 )
2018
28
Influence of <i>FTO</i> rs9939609 polymorphism on appetite, ghrelin, leptin, IL6, TNFI+ levels, and food intake of women with morbid obesity. ( 29785132 )
2018
29
Influence of Drain Placement on Postoperative Pain Following Laparoscopic Roux-en-Y Gastric Bypass for Morbid Obesity: Randomized Controlled Trial. ( 29971581 )
2018
30
Prader-Willi syndrome and early-onset morbid obesity NIH rare disease consortium: A review of natural history study. ( 29271568 )
2018
31
Effect of Morbid Obesity on Midurethral Sling Efficacy for the Management of Stress Urinary Incontinence. ( 29734200 )
2018
32
Characterization of Metabolomic Profile Associated with Metabolic Improvement after Bariatric Surgery in Subjects with Morbid Obesity. ( 29893570 )
2018
33
AA amyloidosis associated with morbid obesity (clinical case). ( 30527964 )
2018
34
Medial Arm Flap: An Unexplored Option for Autologous Breast Reconstruction in the Setting of Morbid Obesity. ( 30067528 )
2018
35
Comparing men and women with binge-eating disorder and co-morbid obesity. ( 29493793 )
2018
36
Evaluating feasibility and accuracy of non-invasive tests for nonalcoholic fatty liver disease in severe and morbid obesity. ( 29463916 )
2018
37
Gastroesophageal reflux disease and morbid obesity: evaluation and treatment. ( 30143983 )
2018
38
In response to: Comment on: laparoscopic sleeve gastrectomy combined with Rossetti fundoplication (R-sleeve) for treatment of morbid obesity and gastroesophageal reflux. ( 29571637 )
2018
39
Optimal Gestational Weight Gain for Women with Gestational Diabetes and Morbid Obesity. ( 29497985 )
2018
40
Robotic Versus Laparoscopic Roux-en-Y Gastric Bypass for Morbid Obesity: a Systematic Review and Meta-Analysis. ( 30178157 )
2018
41
Comprehensive Assessment of the Effects of Sleeve Gastrectomy on Glucose, Lipid, and Amino Acid Metabolism in Asian Individuals with Morbid Obesity. ( 30191503 )
2018
42
Morbid obesity and hypertension: The role of perirenal fat. ( 30216641 )
2018
43
Comparative analysis of laparoscopic sleeve gastrectomy and Roux-en-Y gastric bypass procedures for the treatment of morbid obesity. ( 30221633 )
2018
44
Anemia following Roux-en-Y gastric bypass for morbid obesity; a 5-year follow-up study. ( 30231804 )
2018
45
The role of obesity in the fatal outcome of Schaaf-Yang syndrome: Early onset morbid obesity in a patient with a MAGEL2 mutation. ( 30238631 )
2018
46
First Case of Laparoscopic Mini-Gastric Bypass for the Treatment of Morbid Obesity in Severe Haemophilia A. ( 30248701 )
2018
47
Comparative Effectiveness of Different Bariatric Procedures in Super Morbid Obesity. ( 30251091 )
2018
48
Faecal Microbial Markers and Psychobiological Disorders in Subjects with Morbid Obesity. A Cross-Sectional Study. ( 30262766 )
2018
49
Cocaine and amphetamine regulated transcript and brain-derived neurotrophic factor in morbid obesity. One-year follow-up after gastric bypass. ( 30274741 )
2018
50
Abdominal fat tissue echogenicity: a novel marker of morbid obesity. ( 30358874 )
2018

Variations for Morbid Obesity

ClinVar genetic disease variations for Morbid Obesity:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 UCP3 UCP3, IVS6, G-A, +1 single nucleotide variant Conflicting interpretations of pathogenicity
2 PPARG NM_138712.3(PPARG): c.254C> A (p.Pro85Gln) single nucleotide variant Pathogenic rs1800571 GRCh37 Chromosome 3, 12422848: 12422848
3 PPARG NM_138712.3(PPARG): c.254C> A (p.Pro85Gln) single nucleotide variant Pathogenic rs1800571 GRCh38 Chromosome 3, 12381349: 12381349

Expression for Morbid Obesity

LifeMap Discovery
Genes differentially expressed in tissues of Morbid Obesity patients vs. healthy controls: 35
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 GAPDH glyceraldehyde-3-phosphate dehydrogenase Skeletal Muscle - 5.09 0.006
2 SLN sarcolipin Skeletal Muscle - 4.64 0.007
Search GEO for disease gene expression data for Morbid Obesity.

Pathways for Morbid Obesity

Pathways related to Morbid Obesity according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.03 ADRB3 CCK GCG GHRL HCRT INS
2
Show member pathways
13.39 ADIPOQ ADRB3 GCG INS LEP LEPR
3
Show member pathways
12.92 ADRB3 CCK GCG GHRL HCRT LEP
4 12.34 ADIPOQ FTO GCG INS PPARG
5
Show member pathways
12.22 ADIPOQ INS LEP LEPR PPARG
6
Show member pathways
12.07 GCG GHRL INS LEP
8 11.94 ADRB3 GCG MC3R MC4R
9 11.59 INS LPL PPARG
10 11.54 ADIPOQ LEP LEPR
11 11.37 INS LEP LEPR
12 11.33 ADIPOQ FABP2 LPL PPARG
13 11.22 ADIPOQ INS LEP LPL PPARG RETN
14
Show member pathways
11.09 CRP LEP LEPR
15 10.94 ADIPOQ LEP PPARG
16 10.84 ADIPOQ LEP PPARG

GO Terms for Morbid Obesity

Cellular components related to Morbid Obesity according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.65 ADIPOQ CCK CRP GCG GHRL INS
2 extracellular region GO:0005576 9.4 ADIPOQ CCK CRP GCG GHRL HCRT
3 secretory granule lumen GO:0034774 9.33 GCG GHRL INS

Biological processes related to Morbid Obesity according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 9.96 ADRB3 CCK GCG GHRL HCRT INS
2 positive regulation of MAPK cascade GO:0043410 9.84 ADRB3 INS LEP
3 adenylate cyclase-activating G protein-coupled receptor signaling pathway GO:0007189 9.84 ADRB3 GCG MC3R MC4R
4 response to nutrient GO:0007584 9.82 ADIPOQ LEP PPARG
5 response to insulin GO:0032868 9.8 LEP MC4R RETN
6 glucose metabolic process GO:0006006 9.8 ADIPOQ GHRL INS LEP
7 regulation of blood pressure GO:0008217 9.77 LEP MC3R PPARG
8 glucose homeostasis GO:0042593 9.77 ADIPOQ INS LEP LEPR PPARG
9 response to nutrient levels GO:0031667 9.76 ADIPOQ GHRL LEP
10 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 9.73 ADRB3 GCG MC3R MC4R
11 eating behavior GO:0042755 9.7 CCK HCRT LEP
12 negative regulation of gluconeogenesis GO:0045721 9.69 ADIPOQ INS LEPR
13 temperature homeostasis GO:0001659 9.66 FTO HCRT
14 positive regulation of cellular protein metabolic process GO:0032270 9.66 ADIPOQ INS
15 positive regulation of insulin receptor signaling pathway GO:0046628 9.65 INS LEP
16 regulation of fat cell differentiation GO:0045598 9.65 LEP PPARG
17 fatty acid oxidation GO:0019395 9.65 ADIPOQ PPARG
18 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.65 ADIPOQ CRP PPARG
19 sexual reproduction GO:0019953 9.64 LEP LEPR
20 adult feeding behavior GO:0008343 9.63 GHRL LEP
21 negative regulation of blood vessel diameter GO:0097756 9.63 CRP INS
22 regulation of feeding behavior GO:0060259 9.63 LEPR MC3R MC4R
23 leptin-mediated signaling pathway GO:0033210 9.62 LEP LEPR
24 feeding behavior GO:0007631 9.62 GCG HCRT MC4R PYY
25 negative regulation of appetite GO:0032099 9.61 CCK LEP
26 negative regulation of lipid storage GO:0010888 9.61 CRP LEP
27 negative regulation of acute inflammatory response GO:0002674 9.59 INS PPARG
28 regulation of bone remodeling GO:0046850 9.58 LEP LEPR
29 negative regulation of feeding behavior GO:2000252 9.58 INS MC4R RETN
30 regulation of brown fat cell differentiation GO:0090335 9.57 FTO LEP
31 regulation of metabolic process GO:0019222 9.56 LEP MC4R
32 bone growth GO:0098868 9.55 LEP LEPR
33 energy reserve metabolic process GO:0006112 9.46 ADRB3 LEP LEPR MC4R
34 positive regulation of cold-induced thermogenesis GO:0120162 9.43 ADIPOQ ADRB3 GHRL HCRT LEP LEPR
35 regulation of signaling receptor activity GO:0010469 9.28 ADIPOQ CCK GCG GHRL HCRT INS

Molecular functions related to Morbid Obesity according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.88 ADIPOQ CRP GCG INS LEPR PPARG
2 neuropeptide binding GO:0042923 9.43 MC3R MC4R
3 peptide hormone binding GO:0017046 9.43 LEPR MC3R MC4R
4 peptide hormone receptor binding GO:0051428 9.37 CCK LEP
5 melanocortin receptor activity GO:0004977 9.32 MC3R MC4R
6 hormone activity GO:0005179 9.23 ADIPOQ CCK GCG GHRL INS LEP
7 melanocyte-stimulating hormone receptor activity GO:0004980 9.16 MC3R MC4R
8 neuropeptide hormone activity GO:0005184 9.13 CCK HCRT PYY

Sources for Morbid Obesity

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....